title: [PHARMACOLOGICAL CORRECTION OF APOPTOSIS LEVEL OF CORTICAL NEURONS IN AGED HER2/NEU TRANSGENIC MICE].
abstract: Neurodegenerative changes and neuronal death are the basis for development of the nervous system aging. We investigated the mechanism of apoptosis of the sensorimotor cortex neurons of transgenic mice HER2/neu during aging, changes in the cortex function and the participation of exogenous neurometabolites (cytoflavin, piracetam) in regulation of neuronal death and locomotor and psycho-emotional status of mice. The level of apoptosis and expression of apoptosis markers (TUNEL, immunohistochemistry, Western blotting) in HER2/neu transgenic mice as compared to wild type mice (FBV line) were determined. In aging FBV mice the basal activity was shown to decrease and anxiety to increase correlating with the high level of neuronal apoptosis. We identified behavioral characteristics of transgenic HER2/neu mice and found that their low basal activity does not change with aging. Previously we have shown that in this strain of mice the apoptosis level is low, without any age-related changes, due to the suppression, first of all, of the p53-dependent pathway by HER2 (tyrosine kinase receptor) overexpression. Cytoflavin and piracetam were revealed to possess a marked neuroprotective effect, preserving and restoring functions of the nervous system (improving locomotion and psychological status) in both strains of mice. The effect of neurometabolites studied on neuronal apoptosis is ambiguous. In case of its low level it is a moderate stumulation of apoptosis via the external p53-dependent pathways with activation of caspase-3 in transgenic HER2/neu mice with high carcinogenesis level that can possibly prevent tumor development. On the contrary, in old wild-type animals we observed a significant decrease of age-dependent apoptosis level (by stimulating expression of the anti-apoptotic protein Mcl-1), which prevents neurodegeneration.
authors.forename: E D
authors.initials: ED
authors.lastname: Bazhanova
authors.forename: Yu O
authors.initials: YO
authors.lastname: Kozlova
authors.forename: V N
authors.initials: VN
authors.lastname: Anisimov
authors.forename: D S
authors.initials: DS
authors.lastname: Sukhanov
authors.forename: D L
authors.initials: DL
authors.lastname: Teply
mesh_terms: D000818:Animals; D017209:Apoptosis; D002540:Cerebral Cortex / Q000166:cytology / Q000187:drug effects* / Q000254:growth & development; D004338:Drug Combinations; D005486:Flavin Mononucleotide / Q000494:pharmacology*; D007290:Inosine Diphosphate / Q000494:pharmacology*; D051379:Mice; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D018696:Neuroprotective Agents / Q000494:pharmacology*; D009536:Niacinamide / Q000494:pharmacology*; D010889:Piracetam / Q000494:pharmacology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D013386:Succinates / Q000494:pharmacology*
chemical_list: D004338:Drug Combinations; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate; D018696:Neuroprotective Agents; D009536:Niacinamide; D010889:Piracetam; D018719:Erb-b2 Receptor Tyrosine Kinases; D013386:Succinates; C507879:cytoflavin; C524056:Erbb2 protein, mouse